Clinical Trial Update: Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (ID-MAGIC) is evaluating individualized dosing of ganciclovir in immunocompromised children with Cytomegalovirus infection. Recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: Murdoch Childrens Research Institute | Conditions: Cytomegalovirus Viraemia | Phase 2 | Status: RECRUITING